ANDA 206029, held by Lupin. Pitavastatin Calcium.
As of Nov 16, 2026, ANDA 206029 (Pitavastatin Calcium), held by Lupin, was first approved by FDA on Nov 20, 2023, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 20, 2023 | Original application | Approved | None posted |
| Pitavastatin CalciumEQ 1MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 2MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 4MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Nov 20, 2023 | Original application | Approved | None posted |
| Nov 20, 2023 | Supplement 1 | Approved | None posted |
| Nov 20, 2023 | Supplement 2 | Approved | None posted |
| Nov 20, 2023 | Supplement 3 | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters